Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.
- New Empax clinic at Matilda Nepean Private Hospital in NSW
- Treatment bed capacity rises to 18 across five locations
- Authorised Prescriber network doubles to 12 psychiatrists
- Clinic launch targeted for Q3 2026, pending approvals
- Partnership strengthens Empax Global Partnership Program
Strategic Entry into Australia’s Largest Mental Health Market
Emyria Limited (ASX:EMD) has secured a partnership with Matilda Healthcare to establish its first Empax clinic in New South Wales, marking a significant milestone in its national expansion. The new clinic, set for Kingswood in Western Sydney, will add four treatment beds, bringing the Empax network’s total capacity to 18 beds across Australia’s four most populous states. This move positions Emyria to tap into New South Wales’ substantial mental health demand, serving a catchment of over 2.5 million people and extending reach into underserved regional areas such as Dubbo and Tamworth.
The Kingswood location was selected for its strategic access and modern hospital infrastructure, with the clinic’s operational commencement targeted for the third quarter of 2026, contingent on regulatory approvals and final licence agreements. This expansion complements Emyria’s existing clinics in Perth, Brisbane, and the Mornington Peninsula, creating a coast-to-coast footprint that enhances the company’s clinical delivery and data collection capabilities.
Growing Clinical Workforce and Prescriber Network
Emyria’s Authorised Prescriber (AP) network has doubled in size, with six new psychiatrists recently approved by regulators, increasing the total to 12. These new APs will support operations in Perth, Brisbane, and Mornington Peninsula clinics. Additionally, eight psychiatrists are scheduled to undergo Empax training in New South Wales in June, aiming to bolster the clinical workforce ahead of the new clinic’s launch.
This workforce growth signals increasing psychiatrist acceptance of Emyria’s clinical model and infrastructure, which is critical for scaling psychedelic-assisted therapies. The recruitment drive in New South Wales, initiated earlier this year, reflects the company’s proactive approach to building capacity in Australia’s largest mental health market amid rising psychological injury claims and demand for innovative treatments. This development aligns with the company’s broader strategy to strengthen its national presence and clinical capabilities, as seen in its recent clinical recruitment drive in NSW.
Enhancing the Empax Global Partnership Program
The new clinic at Matilda Nepean Private Hospital also supports Emyria’s recently launched Empax Global Partnership Program, which aims to provide international drug sponsors with a scalable clinical delivery platform. By expanding its geographic footprint and treatment capacity, Emyria enhances its ability to participate in global psychedelic therapy trials and drug development partnerships.
The company’s Executive Chair Greg Hutchinson emphasised that the NSW expansion, combined with the Global Partnership Program and growing AP approvals, advances Emyria’s ambition to be a leading platform for advanced mental health therapies in Australia and a global partner for international drug sponsors. This follows the company’s recent announcement of the Global Partnership Program launch and operational progress across multiple states, including the Victorian clinic opening slated for Q2 2026 and ongoing revenue growth from insurer-funded clinics, as detailed in the national clinic network update.
Commercial Terms and Operational Model
The agreement with Matilda Healthcare grants Emyria exclusive rights to provide psychedelic-assisted therapy at the Kingswood facility, with a three-year initial term and options to renew. Emyria will supply the clinical team and care model, while Matilda provides licensed hospital space, Schedule 8 licensure, and secure drug storage. Licence fees will be paid monthly, with rates increasing in the second year. The partnership also includes first right of refusal for other Matilda sites, potentially facilitating further expansion.
While the binding terms cover key commercial and exclusivity provisions, the final licence agreement remains subject to negotiation and regulatory approvals, introducing some timing and execution uncertainty. Nevertheless, this deal marks a notable step in Emyria’s strategy to build national scale and clinical infrastructure for psychedelic-assisted mental health treatments.
Bottom Line?
Emyria’s NSW clinic launch will test its ability to convert regulatory approvals into operational scale, crucial for sustaining momentum in the competitive psychedelic therapy space.
Questions in the middle?
- How swiftly will regulatory approvals and licence agreements materialise to meet the Q3 2026 target?
- What impact will the NSW clinic have on patient access and treatment outcomes in underserved regional areas?
- Can Emyria maintain its clinical workforce growth amid increasing competition for trained psychiatrists?